Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Volastra Therapeutics

Request full access

Developing novel therapies for patients with metastatic cancers

New York City, United StatesFounded 2019Biotech & Life Sciences

About Volastra Therapeutics

Volastra Therapeutics is a clinical-stage biopharmaceutical startup that operates in the healthcare sector, specifically in the field of cancer research and treatment. The company's primary focus is on the discovery and development of cancer drugs that target chromosomal instability (CIN), a characteristic found in 60-80% of all tumors and often associated with aggressive disease and poor survival rates.

Volastra's business model revolves around the development of innovative treatments and their subsequent commercialization. The company's main clients are patients suffering from cancer, particularly those with aggressive forms of the disease. The company generates revenue through the sale of its developed drugs and treatments.

Currently, Volastra has two lead clinical programs in progress, both of which target KIF18A, a protein that plays a crucial role in the division of cancer cells. The company recently announced the dosing of the first patient in a Phase I/II clinical trial evaluating one of their novel KIF18A inhibitors, VLS-1488.

In addition to its clinical trials, Volastra is also actively involved in research and development. The company recently presented preclinical data on two of its novel KIF18A inhibitors at the AACR 2023 conference. This indicates that the company is not only focused on the commercialization of its existing treatments but is also dedicated to the discovery of new, potentially more effective cancer treatments.

Source: Dealroom company data

At a glance

Status
Operational
Employees
42
Open positions
2
Dealroom signal
64.5/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing May 2024 $15M $60M Undisclosed ↗
SERIES AOther financing Mar 2023 $60M $240M Meyer Ventures · Vida Ventures · Eli Lilly · Catalio Capital Management ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Volastra Therapeutics website traffic

Latest recorded traffic for Volastra Therapeutics is 3.7K monthly website visits, up 60.9% over the last three months. Volastra Therapeutics's team declined 2.3% over the past year.

Latest monthly visits3.7K 3-month web change+60.9% 1-year team growth-2.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Volastra Therapeutics in the New York City ecosystem

Live from Dealroom

The Volastra Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed7 investors entered at this stage

Series A3 investors entered at this stage

  • Meyer Ventures
  • Eli Lilly
  • Cornell University

Other known investors1 additional known investor

  • Cornell Tech
Team profiled 7 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States94.1%
🇧🇷 Brazil2.9%
🇰🇪 Kenya2.9%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Volastra Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Volastra Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.